Spatial Immune Organization Associates with Response to CD40 Agonism in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer: A Phase I Trial.
Osorio Juan C JC, Blanchard Lucas L, Yao Ning N, Alam Syed M SM et al.
CD40 agonists activate dendritic cells (DCs) and promote T-cell antitumor immunity, but clinical development has been limited by systemic toxicity and incomplete understanding of determinants of response. In this phase I study (NCT05126472), we evaluated the safety, preliminary clinical activity, and spatial immune correlates of response to intravesical Fc-optimized CD40 agonist 2141-V11 in 25 patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC). Patients received weekly intravesical instillations for 3 weeks, with retreatment at weeks 13 and 25 based on disease status. Primary objectives were safety, tolerability, and determination of the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D). Secondary endpoints included pharmacokinetics and preliminary clinical activity. Exploratory endpoints including multiplex spatial profiling on tumor specimens to define correlates of response. Intravesical 2141-V11 was well tolerated, and the MTD was not reached. The RP2D was established at 70 mg. Preliminary clinical activity was observed in 40% of patients, with a median response duration of 20 months. Clinical response was associated with distinct organization of tertiary lymphoid structures, characterized by the presence of DC-CXCL13+ CD4+ and CD8+ T cell triads. Following treatment, responders exhibited decreased proximity between DCs and regulatory T cells (Tregs), whereas non-responders exhibited increased DC-Treg proximity. Intravesical 2141-V11 demonstrated a favorable safety profile and preliminary antitumor activity. Spatial profiling revealed immune-cell organizations associated with clinical response, identifying candidate biomarkers and potential strategies for therapeutic combinations. These findings support further clinical evaluation of intravesical 2141-V11 in phase II studies.